Anavex Life Sciences Corp (AVXL)

[Investor2014]

But A2-73 isn't being withheld from the placebo group of Anavex trial participants. In the P2a trial there was no placebo group and after the trial and its extensions ended all patients that remained were offered SAS Cat B compassionate continue used of A2-73. Missling believes that may amount to about 10 patients as of some months ago.

The P2b/3 study patients that continued into in the OLE study and its extension are all offered A2-73 whether they came out of the trial placebo or drug arms.

AD patients around the world that have not participated in the Anavex AD trials are of course not offered A2-73 until those trials may sufficiently prove that A2-73 is safe and effective and marketing approval is granted.

We will know better, maybe late this year or Feb'ish 2023, if certain groups of AD patients in the future might be offered A2-73 based on the P2b/3 AD trial data analysis and readout. If that looks good, then and NDA will be filed and A2-73 may be approved by agencies around the world available for prescription to those AD patients that may benefit according labelling.